Genes in the cluster along with the pathways as annotated by experts

	Expert Annotation	
Treatment	Pathway	Regulation Type
RAF1_WT.1	Canonical MAPK	Activator
BRAF_WT.1	Canonical MAPK	Activator
BRAF_WT.2	Canonical MAPK	Activator
RAF1_WT.2	Canonical MAPK	Activator
MOS_WT.1	MAPK	Activator
MOS_WT.2	MAPK	Activator

How similar is this cluster to the other clusters?



Top 5 genes negatively correlated to the cluster

	Expert Annotation			
Treatment	Pathway	Regulation Type	Mean Correlation	Standard Deviation
RBPJ_WT.1	NOTCH	Activator	-0.60	0.07
ERN1_WT.1	Canonical ER Stress/UPR	Activator	-0.55	0.06
XBP1_WT.1	Canonical ER Stress/UPR	Activator	-0.51	0.09
RBPJ_WT.2	NOTCH	Activator	-0.49	0.10
YAP1_WT.3	Canonical Hippo	Inhibitor	-0.48	0.11

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?



Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.52)	Mean ± standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling ± standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized
BRD-K62246028-001-05-6 T5321448 AC1M8FFC MLS000772051 HMS2744H14 ZINC12484090 SMR000376604 PubChem CID : 2485743		0.85 (in 2 replicates)	0.56 ± 0.06 Treatment / Score BRAF_WT.1 0.61 BRAF_WT.2 0.57 MOS_WT.1 0.62 MOS_WT.2 0.53 RAF1_WT.1 0.59 RAF1_WT.2 0.47	NA				Total number of assays tested in: 554. Active in the following assays: • Aqueous Solubility from MLSMR Stock Solutions (AID 1996) • Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts (AID 588335)
BRD-K88156935-001-01-8 PubChem CID : 44494858		0.65 (in 4 replicates)	0.52 ± 0.06 Treatment / Score BRAF_WT.1 0.55 BRAF_WT.2 0.59 MOS_WT.1 0.43 MOS_WT.2 0.47 RAF1_WT.1 0.55 RAF1_WT.2 0.53	0.762 ± 0.118 Treatment / Score BRAF_WT.1 0.702 BRAF_WT.2 0.720 MOS_WT.1 0.955 MOS_WT.2 0.748 RAF1_WT.1 0.833 RAF1_WT.2 0.616				Total number of assays tested in: 53.

BRD-K90712953-001-01-1 PubChem CID : 54647902		0.52 (in 3 replicates)	0.48 ± 0.03 Treatment / Score BRAF.WT.1 0.48 BRAF.WT.2 0.52 MOS.WT.1 0.42 MOS.WT.2 0.46 RAF1.WT.1 0.49 RAF1.WT.2 0.50	NA				Total number of assays tested in: 36.
BRD-K48113109-001-01-8 PubCid : 44484731		0.52 (in 3 replicates)	0.47 ± 0.02 Treatment / Score BRAF.WT.1 0.48 BRAF.WT.2 0.49 MOS.WT.1 0.46 MOS.WT.2 0.47 RAF1.WT.1 0.48 RAF1.WT.2 0.45	0.404 ± 0.331 Treatment / Score BRAF.WT.1 0.702 BRAF.WT.2 0.227 MOS.WT.1 0.643 MOS.WT.2 0.748 RAF1.WT.1 0.096 RAF1.WT.2 0.009				Total number of assays tested in: 58.
BRD-K84480302-001-01-1 PubCid : 44485894		0.57 (in 3 replicates)	0.46 ± 0.03 Treatment / Score BRAF.WT.1 0.48 BRAF.WT.2 0.49 MOS.WT.1 0.45 MOS.WT.2 0.44 RAF1.WT.1 0.46 RAF1.WT.2 0.42	0.454 ± 0.336 Treatment / Score BRAF.WT.1 0.121 BRAF.WT.2 0.720 MOS.WT.1 0.717 MOS.WT.2 0.837 RAF1.WT.1 0.138 RAF1.WT.2 0.192				Total number of assays tested in: 48.
BRD-K23688566-001-01-4 PubCid : 54638433		0.54 (in 4 replicates)	0.46 ± 0.04 Treatment / Score BRAF.WT.1 0.47 BRAF.WT.2 0.42 MOS.WT.1 0.47 MOS.WT.2 0.50 RAF1.WT.1 0.46 RAF1.WT.2 0.41	0.900 ± 0.087 Treatment / Score BRAF.WT.1 0.923 BRAF.WT.2 0.881 MOS.WT.1 0.971 MOS.WT.2 0.748 RAF1.WT.1 0.881 RAF1.WT.2 0.994				Total number of assays tested in: 31.
BRD-A41524805-001-05-3 T0507-7807 AC1MUI4A MLS000390919 HMS2601F18 SMR000259956 PubCid : 3618784		0.74 (in 2 replicates)	0.45 ± 0.03 Treatment / Score BRAF.WT.1 0.45 BRAF.WT.2 0.46 MOS.WT.1 0.47 MOS.WT.2 0.45 RAF1.WT.1 0.46 RAF1.WT.2 0.40	NA				• Screen for Chemicals that Inhibit the RAM Network (AID 868) • Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen (AID 1362) • qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization (AID 1468) • MLPCN Streptokinase Expression Inhibition (AID 1662) • Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels (AID 2642) • HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732) • Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4) (AID 463111) • uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190) • Validation (re-confirmation) assay for identification of compounds that inhibit KCNQ1 potassium channels (AID 588353) • Counter screen assay of the parental CHO cells for identification of compounds that inhibit KCNQ1 potassium channels (AID 588366) • Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A) (AID 588511) • Validation assay for identification of compounds that activate the regulator of G-protein signaling 4 (RGS4) (AID 602282) • Counter screen for identification of compounds that activate the regulator of G-protein signaling 4 (RGS4): Non-induced cells with the primary screen assay (AID 602283) • uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449) • Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504) • Specificity screen against KCNQ2 for identification of compounds that inhibit KCNQ1 potassium channels (AID 651746) • Specificity screen against KCNQ1/KCNE1 for identification of compounds that inhibit KCNQ1 potassium channels (AID 652147) • QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10. (AID 720582) • QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17. (AID 720648) • Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3). (AID 720704) • Counterscreen for exosite inhibitors of ADAM17: Fluorescence resonance energy transfer (FRET)-based biochemical high throughput screening assay to identify inhibitors of ADAM10 (AID 743256) • QFRET-based biochemical high throughput confirmation assay to identify exosite inhibitors of ADAM17 (AID 743257)
BRD-K09411557-001-05-1 SMR000013142 MLS000032522 AC1LCH7J BDBM43920 HMS2350P13 ZINC789718 STK044827 BAS 05022382 EU-0081084 PubCid : 650152		0.64 (in 4 replicates)	0.44 ± 0.05 Treatment / Score BRAF.WT.1 0.46 BRAF.WT.2 0.45 MOS.WT.1 0.52 MOS.WT.2 0.43 RAF1.WT.1 0.45 RAF1.WT.2 0.37	NA				• CYP2C9 Assay (AID 777) • CYP2C19 Assay (AID 778) • Kallikrein 5 1536 HTS (AID 873) • qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase) (AID 894) • Leishmania major promastigote HTS (AID 1063) • Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen (AID 1456) • Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Secondary Assay 2 with KCC2 cells (AID 1715) • Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314) • A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315) • Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus (AID 602277) • qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)

BRD-K91321179-001-05-9
MLS000673882
SMR000297924
AC1NSOH4
Ambcb5904359
BDBM60641
HMS2601A16
ZINC13130666
PubChem CID : 5337291



0.66 (in 2 replicates)

0.44 ± 0.03

Treatment	Score
BRAF.WT.1	0.48
BRAF.WT.2	0.44
MOS.WT.1	0.44
MOS.WT.2	0.47
RAF1.WT.1	0.45
RAF1.WT.2	0.38

NA







Total number of assays tested in: 634. Active in the following assays:

- Screen for Chemicals that Inhibit the RAM Network (AID 868)
- qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)
- qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase (AID 1631)
- Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3) (AID 1800)
- Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents (AID 1903)
- Fluorescence-based confirmation biochemical high throughput screening assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3) (AID 1943)
- 384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC (AID 463187)
- qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1) (AID 485290)
- qHTS Assay for Inhibitors of DNA Polymerase Beta (AID 485314)
- HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS (AID 485317)
- uHTS Colorimetric assay for identification of inhibitors of Scp-1 (AID 493091)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
- Single concentration confirmation of uHTS hits for Scp-1 phosphatase using a colorimetric assay (AID 540281)
- Dose Response confirmation of uHTS hits for Scp-1 phosphatase using a colorimetric assay (AID 540297)
- qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
- qHTS for Inhibitors of Polymerase Iota (AID 588590)
- qHTS for Inhibitors of Polymerase Eta (AID 588591)
- Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5) (AID 602281)
- uHTS identification of inhibitors of NadD in a Colorimetric assay (AID 602399)
- qHTS for Inhibitors of Glutaminase (GLS) (AID 624170)
- qHTS for Inhibitors of Polymerase Eta: Confirmatory Assay for Cherry-picked Compounds (AID 720502)
- qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)
- qHTS of Trypanosoma Brucei Inhibitors: Confirmatory Assay for Cherry-picked Compounds (AID 720569)
- qHTS of Trypanosoma Brucei Inhibitors: Orthogonal Assay for Cherry-picked Compounds (AID 720584)

BRD-K97424736-001-06-9
ZINC00366916
AC1LHJBH
MLS001178679
HMS2845M21
ZINC366916
SMR000477411
PubChem CID : 838857



0.57 (in 2 replicates)

0.44 ± 0.10

Treatment	Score
BRAF.WT.1	0.48
BRAF.WT.2	0.57
MOS.WT.1	0.30
MOS.WT.2	0.34
RAF1.WT.1	0.48
RAF1.WT.2	0.48

NA







Total number of assays tested in: 494. Active in the following assays:

- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- Luminescence Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301 (AID 2716)

BRD-K76988892-001-01-9
PubChem CID : 54646031

NA (in 1 replicates)

-0.57 ± 0.04

Treatment	Score
BRAF.WT.1	-0.57
BRAF.WT.2	-0.62
MOS.WT.1	-0.53
MOS.WT.2	-0.52
RAF1.WT.1	-0.62
RAF1.WT.2	-0.56

0.245 ± 0.100

Treatment	Score
BRAF.WT.1	0.298
BRAF.WT.2	0.280
MOS.WT.1	0.357
MOS.WT.2	0.252
RAF1.WT.1	0.065
RAF1.WT.2	0.219

NA

Total number of assays tested in: 41.

BRD-K76218980-001-11-3
nikkomycin z
AC1NUQ0P
MLS000028371
HMS2233C10
ZINC366916
SMR000058642
PubChem CID : 5458181



NA (in 1 replicates)

-0.56 ± 0.02

Treatment	Score
BRAF.WT.1	-0.56
BRAF.WT.2	-0.56
MOS.WT.1	-0.57
MOS.WT.2	-0.54
RAF1.WT.1	-0.60
RAF1.WT.2	-0.55

NA





Total number of assays tested in: 698. Active in the following assays:

- qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)
- Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant C. albicans Growth in the Presence of Fluconazole (AID 2423)
- Fluorescence Cell-Based Retest of C. albicans Growth in the Presence of Fluconazole (AID 2467)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
- qHTS of TDP-43 Inhibitors (AID 652104)

BRD-K88806900-001-05-0
BAS 00678327
ZINC00320223
AC1LFUQ3
MLS000556737
ARONIS25745
HMS2331P05
ZINC320223
STL289957
SMR000175822
KB-120261
ST45054549
PB184801722
PubChem CID : 809168



NA (in 1 replicates)

-0.56 ± 0.04

Treatment	Score
BRAF.WT.1	-0.55
BRAF.WT.2	-0.59
MOS.WT.1	-0.51
MOS.WT.2	-0.52
RAF1.WT.1	-0.61
RAF1.WT.2	-0.58

NA







Total number of assays tested in: 666. Active in the following assays:

- A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators (AID 485347)
- uHTS Colorimetric assay for identification of inhibitors of Scp-1 (AID 493091)

BRD-K16172779-001-01-1
PubChem CID : 54631934

0.76 (in 4 replicates)

-0.56 ± 0.06

Treatment	Score
BRAF.WT.1	-0.60
BRAF.WT.2	-0.62
MOS.WT.1	-0.50
MOS.WT.2	-0.50
RAF1.WT.1	-0.61
RAF1.WT.2	-0.53

0.352 ± 0.277

Treatment	Score
BRAF.WT.1	0.082
BRAF.WT.2	0.263
MOS.WT.1	0.882
MOS.WT.2	0.252
RAF1.WT.1	0.250
RAF1.WT.2	0.384

Total number of assays tested in: 39. Active in the following assays:

- Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_HTS_Activity (AID 624255)

BRD-K19019278-001-01-7 PubChem CID : 54631454		0.74 (in 4 replicates)	-0.55 ± 0.07 Treatment / Score BRAF.WT.1 -0.61 BRAF.WT.2 -0.64 MOS.WT.1 -0.47 MOS.WT.2 -0.48 RAF1.WT.1 -0.61 RAF1.WT.2 -0.53	0.329 ± 0.172 Treatment / Score BRAF.WT.1 0.283 BRAF.WT.2 0.280 MOS.WT.1 0.231 MOS.WT.2 0.252 RAF1.WT.1 0.250 RAF1.WT.2 0.678				Total number of assays tested in: 34.
BRD-K86621086-001-01-0 PubChem CID : 44494594		0.79 (in 4 replicates)	-0.55 ± 0.09 Treatment / Score BRAF.WT.1 -0.60 BRAF.WT.2 -0.66 MOS.WT.1 -0.44 MOS.WT.2 -0.45 RAF1.WT.1 -0.60 RAF1.WT.2 -0.56	NA				Total number of assays tested in: 50. Active in the following assays: • HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity (AID 651654)
BRD-K42959654-001-01-9 PubChem CID : 54646040		NA (in 1 replicates)	-0.55 ± 0.05 Treatment / Score BRAF.WT.1 -0.56 BRAF.WT.2 -0.61 MOS.WT.1 -0.51 MOS.WT.2 -0.50 RAF1.WT.1 -0.61 RAF1.WT.2 -0.53	0.303 ± 0.219 Treatment / Score BRAF.WT.1 0.708 BRAF.WT.2 0.280 MOS.WT.1 0.288 MOS.WT.2 0.252 RAF1.WT.1 0.250 RAF1.WT.2 0.038				Total number of assays tested in: 42.
BRD-K53719842-001-06-5 SMR000206475 MLS000582489 HMS2517A04 HMS3376B19 ZINC4958796 PubChem CID : 12004860		NA (in 1 replicates)	-0.55 ± 0.03 Treatment / Score BRAF.WT.1 -0.55 BRAF.WT.2 -0.52 MOS.WT.1 -0.54 MOS.WT.2 -0.59 RAF1.WT.1 -0.58 RAF1.WT.2 -0.52	NA				Total number of assays tested in: 633. Active in the following assays: • Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao. (AID 1441) • Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions. (AID 1504) • MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen (AID 1832) • Fluorescent Polarization Homogeneous Dose Retest to Confirm Inhibitors of Mex-5 Binding to TCR-2 (AID 449745) • Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation (AID 504834)
BRD-K24873600-001-01-9 PubChem CID : 54641067		NA (in 1 replicates)	-0.55 ± 0.05 Treatment / Score BRAF.WT.1 -0.56 BRAF.WT.2 -0.62 MOS.WT.1 -0.51 MOS.WT.2 -0.48 RAF1.WT.1 -0.59 RAF1.WT.2 -0.51	NA				Total number of assays tested in: 38.
BRD-K57140889-001-01-5 PubChem CID : 54632228		0.78 (in 4 replicates)	-0.54 ± 0.09 Treatment / Score BRAF.WT.1 -0.59 BRAF.WT.2 -0.64 MOS.WT.1 -0.41 MOS.WT.2 -0.47 RAF1.WT.1 -0.59 RAF1.WT.2 -0.56	0.575 ± 0.332 Treatment / Score BRAF.WT.1 0.298 BRAF.WT.2 0.280 MOS.WT.1 0.796 MOS.WT.2 0.252 RAF1.WT.1 0.969 RAF1.WT.2 0.856				Total number of assays tested in: 35.